# Longview Ventures

> Longview Ventures is a VC fund in Boston backing Health Care and Biotechnology. See 14 investments, check sizes, portfolio. Updated Aug 2026.

- Type: VC Fund
- Location: Boston, United States
- Total investments: 14
- Last investment: May 2025
- Lead investor: 0%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/company/longview-ventures
- Website: https://broadviewventures.org/longview-ventures

Longview Ventures is an independent investmenter that makes investments in select companies from the broadview portfolio.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Health Care | 7 | 50% |
| Biotechnology | 6 | 43% |
| Medical Device | 4 | 29% |
| Biopharma | 2 | 14% |
| Therapeutics | 2 | 14% |

11 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 5 | 36% |
| Series B | 3 | 21% |
| Series C | 1 | 7% |
| Funding Round | 1 | 7% |
| Post-IPO Equity | 1 | 7% |

6 stages tracked in total.

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 6 | 43% |
| Canada | 1 | 7% |
| Denmark | 1 | 7% |
| Switzerland | 1 | 7% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| HAYA Therapeutics | HAYA Therapeutics is a biotechnology company developing precision RNA-guided medicines that target the dark genome. The company leverages its proprietary platform to uncover new insights into disease-associated cell states and the long non-coding RNAs (lncRNAs) that control them. Its lead candidate, HTX-001, is being developed as a potentialtreatment for heart failure. In addition, the company is advancing a pipeline of precision therapies that target lncRNAs for cell-specific treatment of conditions affecting other tissues. | $65M | Series A | May 08, 2025 |  |
| Puzzle Medical Devices | Puzzle Medical is developing the ModulHeart, a modular percutaneous heart pump designed to reduce cardiac afterload and improve renal perfusion in patients with advanced heart failure who are not candidates for heart transplant or surgical mechanical circulatory support. The device’s modular design allows for hemodynamic support through multiplepumps anchored in parallel in the descending aorta. The design is expected to increase accessibility by enabling safe percutaneous implantation to support both renal and cardiac function, with low risk of bleeding, stroke, and pump thrombosis, while providing sustained symptom relief, reduced re-hospitalizations and improved overall quality of life. To date, Puzzle Medical has successfully:○ completed its first-in-human study with all patients experiencing improvements in cardiac and kidney function (2022); ○ completed a Seed financing round (2021); ○ built a strong Key Opinion Leaders committee (2021); ○ received U.S. Food and Drug Administration (FDA) Breakthrough Device Designation (2021). | $30.2M | Series A | Apr 08, 2025 |  |
| Alleviant Medical | Alleviant Medical focuses on developing a minimally-invasive medical device to treat congestive heart failure. Its proprietary transcatheter technology is designed to create a paradigm shift in the treatment of heart failure by relieving patient symptoms, improving quality of life, and reducing hospital readmissions for over 6 million Americanscurrently suffering from this disease. | $90M | Venture - Series Unknown | Jan 14, 2025 |  |
| Antag Therapeutics | Antag Therapeutics operator of a biotechnology company intended to develop metabolic and anti-obesity therapeutic drugs.The company specializes in the development of peptide-based GIP receptor antagonist in order to monitor dietary-related metabolic diseases through the infusion, enabling the healthcare industry to decrease blood flow and lipiduptake in adipose tissue in an efficient manner. | $84.1M | Series A | Dec 04, 2024 |  |
| AtaCor Medical | AtaCor Medical Inc., is a San Clemente-based medical device maker. It designs innovative solutions to deliver temporary, interim, and permanent cardiac pacing when, and where it matters most. | $28M | Series C | Apr 24, 2024 |  |
| Basking Biosciences | Basking Biosciences is a startup that’s developing a therapy to restore blood flow to the brain during ischemic stroke, preventing hemorrhage and long-term damage. | $55M | Series A | Jan 30, 2024 |  |
| Comanche Biopharma | Comanche Biopharma is a biopharmaceutical company that develops siRNA therapy for the treatment of preeclampsia. The company aims to lower the risks of pregnancy and prematurity by safely sustaining natural pregnancy and allowing fetal maturation. | $75M | Series B | Jan 17, 2024 |  |
| Comanche Biopharma | Comanche Biopharma is a biopharmaceutical company that develops siRNA therapy for the treatment of preeclampsia. The company aims to lower the risks of pregnancy and prematurity by safely sustaining natural pregnancy and allowing fetal maturation. | $36.1M | Series A | May 12, 2023 |  |
| Puzzle Medical Devices | Puzzle Medical is developing the ModulHeart, a modular percutaneous heart pump designed to reduce cardiac afterload and improve renal perfusion in patients with advanced heart failure who are not candidates for heart transplant or surgical mechanical circulatory support. The device’s modular design allows for hemodynamic support through multiplepumps anchored in parallel in the descending aorta. The design is expected to increase accessibility by enabling safe percutaneous implantation to support both renal and cardiac function, with low risk of bleeding, stroke, and pump thrombosis, while providing sustained symptom relief, reduced re-hospitalizations and improved overall quality of life. To date, Puzzle Medical has successfully:○ completed its first-in-human study with all patients experiencing improvements in cardiac and kidney function (2022); ○ completed a Seed financing round (2021); ○ built a strong Key Opinion Leaders committee (2021); ○ received U.S. Food and Drug Administration (FDA) Breakthrough Device Designation (2021). | $25.3M | Series A | Feb 09, 2023 |  |
| Alleviant Medical | Alleviant Medical focuses on developing a minimally-invasive medical device to treat congestive heart failure. Its proprietary transcatheter technology is designed to create a paradigm shift in the treatment of heart failure by relieving patient symptoms, improving quality of life, and reducing hospital readmissions for over 6 million Americanscurrently suffering from this disease. | $73.7M | Venture - Series Unknown | Jan 26, 2023 |  |

10 of 14 investments shown.

## Co-investors
- [Portfolia](https://shizune.co/investors/profile/portfolia) — VC Fund, 4 deals together
- [Catalyst Health Ventures](https://shizune.co/investors/profile/catalyst-health-ventures) — VC Fund, 3 deals together
- Longview Ventures — VC Fund, 3 deals together
- [S3 Ventures](https://shizune.co/investors/profile/s3-ventures) — VC Fund, 3 deals together
- [Vensana Capital](https://shizune.co/investors/profile/vensana-capital) — VC Fund, 3 deals together
- [Broadview Ventures](https://shizune.co/investors/profile/broadview-ventures) — VC Fund, 2 deals together

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

## FAQ

### What does Longview Ventures invest in?

Longview Ventures invests primarily in Health Care, Biotechnology and Medical Device startups, most often at Series A and Series B stage. Most of the 14 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Longview Ventures last invest?

The most recent investment recorded for Longview Ventures closed in May 2025. Shizune tracks 14 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co